Analytical and Functional Sensitivity of PSA Assays
During the last few years both clinical investigators and commercial concerns have made efforts to produce PSA assays with improved detection limits (e.g., [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] ). The well-accepted rationale behind more-sensitive PSA assays is that cancer relapse will be detected earlier if patients are monitored with moresensitive methods. An ultrasensitive PSA assay is characterized by its lowest limit of detection (LLD), which, by definition, is the least amount of analyte that can be detected with a predetermined confidence, usually 95% or 99%. The LLD commonly is calculated by analyzing the zero calibrator and the lowest-concentration calibrator of the assay many times (e.g., 12-20 replicates). From these data, the SD of the zero signal is calculated.
The LLD is the analyte concentration that corresponds to the zero signal + 2 SD (for 95% confidence) or + 3 SD (for 99% confidence), calculated from the slope of the calibration curve between the zero and the first calibrators. From these calculations, one can determine the factors that affect the LLD. In a "sandwich-type" assay with variable zero signal, variable precision of the zero signal, and variable signal of the lowest-concentration calibrator ( Vessella et al. [5] introduced the term "biological detection limit" (BDL), which they determined by adding the LLD and 2 SD of the patients' sample interassay imprecision data generated should be based on interassay imprecision profiles established with patients' sera at concentrations 2-4 times the LLDs; in general, interassay imprecision at the clinically useful cutoff point should be 20%. measures; e.g., a biochemical relapse will be considered to be established only after two consecutive sequential samples show a PSA increase that at least doubles the initial PSA concentration.
These criteria must be evaluated clinically; however, a similar set of interpretative criteria were recently shown to work well in a small group of patients whose clinical outcomes were known [13] .
PSA Calibrator Matrix and Quality-Control Sera
Stamey suggests [1] that LLD values based only on assays with bovine serum albumin (BSA)-based reagents bear no relationship to relevant clinical values in humans. We believe this is an overstatement.
BSA-based calibrators are now used not only for PSA but also for many other analytes and are well established. The advantages of BSA matrix are well-recognized: e.g., no infectivity, low cost, excellent reproducibility and consistency, absence of analyte, and extended analyte stability. For PSA assays, other alternatives could be animal sera, female sera, and male sera devoid of PSA. Animal sera are used already and the same argument as is made against BSA can be used against them. Female sera are not always devoid of PSA, as we have shown already [14] , and sera from pregnant women have an even higher median PSA (unpublished).
Moreover, postprostatectomy serum has, on average, a higher PSA concentration than serum from nonpregnant women [14] . The role of a zero calibrator is to set an average assay signal that corresponds to no analyte presence. In our assay system, a 60 g/L BSA matrix devoid of PSA generates a signal of -1000 arbitrary fluorescence units (AFU), and a PSA calibrator of between 0.000 and 0.001 .tg/L in 14%, and <0.000 in 18%-all concentrations derived by using 60 g/L BSA-based calibrators. If indeed the signal of the 60 g/L BSA solution was set at a higher value than an equivalent serum-based calibrator, this would be an advantage for monitoring postprostatectomy male patients because any detected increase in subsequent sera would be based on even more conservative criteria than the ones already mentioned and published [13] .
Is the immunoreactive
PSA detected at concentrations (e.g.) 0.0l0 j.tg/L in female sera or sera from postprostatectomy patients indeed PSA and not cross-reacting substances or random variations?
We now know that PSA can be produced by female tissues other than the periurethral glands. Normal, benign, and malignant breast tissues produce PSA [15] [16] [17] [18] [19] [20] [21] . PSA is secreted into the lumen of the ducts of the mammary glands and can be detected in breast milk [19] and discharge fluid ( 15 000 i.tg/L; unpublished data). It should thus not be surprising that some PSA from breast tissue, as with prostate tissue, may escape into the female blood circulation.
Other potential sources of PSA in women may be the endometrium [22] or salivary glands [23] . During pregnancy, serum PSA increases in amniotic fluid according to gestational age (f24] and Melegos et al., ms. submitted).
The pattern of PSA changes in maternal serum during gestation is statistically significant and cannot be attributed to random fluctuations. We also found nonrandom associations between serum PSA in nonpregnant females and their ages, and we provided preliminary evidence that the immunoreactive species in normal female serum is PSA bound to a1-antichymotrypsin [14] . In male serum, the situation is clearer. In sequential patients' sera postradical prostatectomy, the PSA concentrations, although undetectable after surgery (<0.00 1 .tg/L) in many patients, became detectable (0.00 1-0.005 g.g/L) and then increased steadily, following an exponential model [13, 25] .Detailed descriptions of these data will be published elsewhere.
Ideally, quality-control specimens for PSA would be developed in authentic male serum, but this is not an absolute necessity. Male quality-control sera can be found from prostatectomy patients and may have serum PSA anywhere between 0.001 and 0.10 j.Lg/L, but commercial availability would be very limited. PSA-supplemented female sera could serve as useful PSA controls to monitor precision even if the PSA subfractions did not match the subfractions in male serum. Animal serum, which is the most readily available, should also be evaluated carefully.
We believe that new PSA assays, designed to monitor patients after radical prostatectomy or for use in other applications such as measurement of PSA in breast tumor cytosolic extracts and female serum during pregnancy, should have FS values between 0.001 and 0.002 g/L (day-to-day CV <20%). These assays should be monitored for imprecision at concentrations of -0.003, 0.010, 0.030, and 0.100 jkg/L and should include calibrators at 0, 0.002, 0.005, 0.020, 0.100, 0.500, and 2.00 jkg/L.
Residual Cancer Detection Limit (RCDL)
Stamey suggests that, were we to follow the recommendations of Vessella et al., the BDL we calculated in our previous report [2] would have been much higher than 0.010 g/L. This is not accurate.
Our LLD, as calculated with the method described, was 0.002 g/L. Our within-run CV at 0.0 16 jg/L, for a human serum sample, was 21.4%. We have thus conservatively calculated our BDL to be 0.010 .tg/L. In our precision studies (Table   1 of reference 2), we found little difference between within-run and day-to-day imprecisions, similar to the findings of others [5] . Consequently, our BDL would have probably been a little but not substantially higher than reported if we were to use day-to-day imprecision data instead of within-day imprecision data. Since publication of that report, we have developed another PSA assay that can detect PSA at 0.001 .tg/L with within-rim imprecision of <20% at PSA >0.002 .tg/L [25] . We disagree with the determination and use of RCDL as described by Stamey. First, he describes such determination as being simpler than the determination of BDL or FS. This does not seem to be the case. For FS studies, one needs a few sera from postradical prostatectomy subjects who were found to have PSA <0.10 g/L by conventional PSA analysis. We have shown that, among these sera, -50% have PSA of 0.005-0.10 g/L; the rest have PSA of 0-0.005 j.g/L. For RCDL determination, one needs sera from extremely well-defined patients: e.g., follow-up >5 years, Gleason score <5, prostatic tissue examination with 3-mm step-sections, and tumor size <0.5 mL. Such sera are not generally available, and unreliable selection will lead to wrong calculations.
The RCDL is based on the unproven premises that a patient cured of prostate cancer should not have any PSA in his serum and that, if a sensitive method detects something, this must be due to random assay variation. In our opinion, the possibility of extraprostatic sources of PSA cannot be excluded. We anticipate that patients will be encountered with post- How sensitive must PSA assays be for relapse to be detected as early as possible? Our data suggest that PSA in -60% of patients decreased to <0.005 JLg/L postsurgery and in -26% decreased to 0.001 p.g/L. Thus, assays with FS around 0.001-0.002 .tg/L should be desirable. Unquestionably, ultrasensitive PSA assays can detect relapse much earlier than conventional assays [8, 11, 13] .However, the detection of biochemical relapse at the earliest possible time depends not only on PSA assay sensitivity but also on other, fundamentally important factors, including:
(a) The frequency of serum sampling. More frequent sampling may facilitate earlier detection of relapse.
(b)The strategy of analyzing samples. Analyzing replicates and including in the same run three sequential sera (the current and previous two) will facilitate identification of PSA changes through minimization of assay variability. (c) The interpretive criteria. These should be established on the basis of clinical outcomes [13] and should be conservative enough to avoid false positives.
(i The doubling time of the tumor [13] 
